Insider Buy ·Filed Jul 31, 2026

ARTV

Artiva Biotherapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001231919-26-000817
Insider cluster: 1 insiders, $2.1M total
Actionable Insight ▲ Bullish

This is a strong insider conviction buy from a major shareholder. Traders should watch for upcoming catalysts (e.g., pipeline updates, partnership news) that may have prompted the accumulation. The sustained buying pattern suggests confidence in near-term value.

DirectionBullish
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
ARTV ▲ +5.02% at T+20d
LONG call ✓ call won +5.02% · α vs SPY +3.78% · entry $10.76 → $11.30
Next anchor: T+60d in 24d
Latest observation: T+41 -30.41% FF3 residual α
Entry anchored
Jul 31, 03:59 PM ET
via exchange tick
T+1d
+2.88%
call +2.88% · α +1.08%
$11.07
settled 2mo ago
T+5d
+4.28%
call +4.28% · α +2.25%
$11.22
settled 8w ago
T+20d
+5.02%
call +5.02% · α +3.78%
$11.30
settled 5w ago
T+60d
—
call — · α —
—
in 24d

Price Chart

Loading chart...

Executive Summary

RA Capital Management, L.P., a director and 10% owner, purchased $2.05M of ARTV shares in four open-market transactions over eight days (July 22-29, 2026). This represents ~0.79% of the $258M market cap and is a strong insider conviction signal, especially given the firm's sustained buying pattern ($5.0M total insider purchases in the last 30 days).

Key Financial Metrics

Direction
buying
Total Value
$2.0M
Insiders
1

Key Facts

  • RA Capital Management (Director, 10% Owner) bought $2.05M of ARTV shares across 4 trades at ~$9.93-$9.99 per share.
  • Total insider purchases in the last 30 days reached $5.0M across 10 transactions.
  • Purchase represents ~0.79% of ARTV's $258M market cap, a significant proportional stake.
  • Analyst consensus is 92% bullish (4 Strong Buy, 7 Buy, 1 Hold).

Financial Impact

Insider purchase of $2.05M (0.79% of market cap) by a 10% owner.

ownership concentrationmarket sentiment

Risk Factors

  • No specific corporate catalyst disclosed; the buy may reflect long-term positioning rather than imminent news.
  • Biotech sector volatility and clinical-stage risk remain.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
INSIDER-BUY Data (Synthetic)0001231919-26-000817
28 reports for ARTV
Performance horizon
87% Hit rate 13 of 15 directional calls best @ T+20▲ +38.82%Jun 8, 2026
Filters
Rows
Reports for ARTV — sortable, filterable
TypeNow
Sep 11, 2026
20d ago
8-K
NEUTRAL ★ 3/10
$10.14 $8.91▼ −12.13%▼ −11.67%$6.86 (−32.35%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 4/10
$10.79 $10.42▼ −3.43%▼ −2.83%$6.86 (−36.42%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 3/10
$10.79 $10.42▼ −3.43%▼ −2.83%$6.86 (−36.42%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 4/10
$10.79 $10.42▼ −3.43%▼ −2.83%$6.86 (−36.42%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 3/10
$10.79 $10.42▼ −3.43%▼ −2.83%$6.86 (−36.42%)
Sep 9, 2026
23d ago
Insider Cluster
BEARISH ★ 5/10
$10.79 $10.42▲ +3.43%▲ +2.83%$6.86 (+36.42%)
Sep 4, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$11.19 $10.88▼ −2.77%▼ −2.22%$6.86 (−38.70%)
Aug 15, 2026
6w ago
Institutional Cluster
BULLISH ★ 6/10
$11.74 $11.68▼ −0.51%▲ +0.16%$6.86 (−41.57%)
Jul 31, 2026
8w ago
Insider Buy
BULLISH ★ 7/10
$10.76 $11.07▲ +2.88%▲ +1.08%$6.86 (−36.25%)
Jul 28, 2026
9w ago
Insider Buy
BULLISH ★ 6/10
$10.53 $10.02▼ −4.84%▼ −3.30%$6.86 (−34.85%)
Showing 10 of 28

US Market Status

Market Open — Closes in 3h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access